Biocon trades higher as its arm gets nod for Posaconazole Delayed-Release tablets from USFDA
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Biocon is currently trading at Rs. 407.70, up by 7.75 points or 1.94% from its previous closing of Rs. 399.95 on the BSE.
The scrip opened at Rs. 403.00 and has touched a high and low of Rs. 410.50 and Rs. 399.60 respectively. So far 214880 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 424.75 on 18-Feb-2021 and a 52 week low of Rs. 314.90 on 25-Oct-2021.
Last one week high and low of the scrip stood at Rs. 410.50 and Rs. 378.20 respectively. The current market cap of the company is Rs. 48990.48 crore.
The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 23.37% and 15.99% respectively.
Biocon’s subsidiary company -- Biocon Pharma has received approval of its ANDA for Posaconazole Delayed-Release tablets from the United States Food and Drug Administration (USFDA). This product is indicated for use in the prevention of certain fungal infections in patients with severely weakened immune systems and is available in 100mg strength. This approval further adds to Biocon’s portfolio of vertically integrated complex drug products.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
